Compare · GILD vs LXEO
GILD vs LXEO
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Lexeo Therapeutics Inc. (LXEO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and LXEO operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $181.46B, about 464.6x LXEO ($390.5M).
- Over the past year, GILD is up 31.5% and LXEO is down 4.3% - GILD leads by 35.8 points.
- Both names hit the wire about 10 times in the past 4 weeks.
- GILD has more recent analyst coverage (25 ratings vs 11 for LXEO).
- Company
- Gilead Sciences Inc.
- Lexeo Therapeutics Inc.
- Price
- $148.29+1.33%
- $4.59-3.26%
- Market cap
- $181.46B
- $390.5M
- 1M return
- +13.02%
- +9.67%
- 1Y return
- +31.54%
- -4.27%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2023
- News (4w)
- 10
- 10
- Recent ratings
- 25
- 11
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC
- FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC
- Director Welters Anthony exercised 18,000 shares at a strike of $61.06 and sold $2,675,220 worth of shares (18,000 units at $148.62) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form N-PX filed by Gilead Sciences Inc.
- Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
- European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
- Director Bluestone Jeffrey exercised 5,000 shares at a strike of $67.04 and sold $725,078 worth of shares (5,000 units at $145.02) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $415,080 worth of shares (3,000 units at $138.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 165,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna exercised 25,000 shares at a strike of $67.07 and sold $3,853,908 worth of shares (28,000 units at $137.64) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 118,234 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M covered exercise/tax liability with 2,908 shares and converted options into 6,002 shares, increasing direct ownership by 58% to 8,454 units (SEC Form 4)
Latest LXEO
- Chief Financial Officer Tamayo Louis Edward sold $20,203 worth of shares (4,117 units at $4.91), decreasing direct ownership by 4% to 92,907 units (SEC Form 4) (tax withholding)
- Chief Executive Officer Townsend Richard Nolan sold $16,562 worth of shares (3,345 units at $4.95), decreasing direct ownership by 0.89% to 374,472 units (SEC Form 4) (withholding tax)
- Chief Operating Officer Otero Jose Manuel sold $6,464 worth of shares (1,304 units at $4.96), decreasing direct ownership by 0.95% to 136,178 units (SEC Form 4) (for tax liability)
- SEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.
- SEC Form 10-Q filed by Lexeo Therapeutics Inc.
- Lexeo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights